The epidemiology of cholangiocarcinoma.

By Y. Shaib, H. B. EL‐SERAG. Seminars in liver disease (Print), 2004

1,264 citations recorded by the source corpus.

Subfields: Pharmacy, Pulmonary and Respiratory Medicine, Surgery

View Paper: https://www.semanticscholar.org/paper/94ddb9debf7f7938027c2d7c45c33e886084d5cb

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Pharmacy

1. G. Gores

In Pulmonary and Respiratory Medicine

1. Sumera I. Ilyas
2. G. Gores
3. H. B. EL‐SERAG

In Surgery

1. Sumera I. Ilyas
2. G. Gores
3. H. B. EL‐SERAG
4. J. Llovet

Citations in the corpus

• Cancer incidence before and after kidney transplantation. (2006, background): “Infection with hepatitis C virus, hepatitis B virus, and liver flukes has been suspected as causing biliary tract cancer.(24,25) For lip cancer, exposure to UV radiation and tobacco products are thought to be important causal factors,(26) but the role of human papillomavirus is under study.”
• Guidelines for the diagnosis and treatment of cholangiocarcinoma: an update (2012, background): “The cause of the rise in CC is unknown and is not explained by improvements in diagnosis.(6) 12e15 There is debate as to whether the rise in intrahepatic CC represents a genuine increase in true parenchymal primary CC.”
• Chronic Inflammation and Cytokines in the Tumor Microenvironment (2014, neutral): “[214] Y.”
• Guidelines for the diagnosis and management of intrahepatic cholangiocarcinoma. (2014, background): “iCCA incidence increased by 165%, during which time no significant changes were found in the proportion of patients with unstaged cancer, localized cancer, microscopic confirmation, or with tumor size <5 cm, suggesting a true increase in iCCA rather than earlier or improved diagnosis [10,11].”
• Pathogenesis, Diagnosis, and Management of Cholangiocarcinoma (2013, background): “1 per 100,000 in Australia.(9,10) Differences in the prevalence of genetic and other risk factors presumably account for this extensive variation.”
• Cholangiocarcinoma — evolving concepts and therapeutic strategies (2017, neutral): “Multiple studies reported that the incidence of iCCA increased by up to 10­fold, while the incidence of pCCA/dCCA decreased at a sim­ ilar or slightly slower rate, over a 2–3­decade period around the turn of the 20 th century in Australia, Japan, the USA, the UK, and across Europe 3,4,18–21 .”
• Risk Factors of Cholangiocarcinoma (2011, background): “Differing exposure to risk factors is thought to account for the varying geographic incidences, with parasitic infections and hepatolithiasis being more prevalent in Asia.(3,5) Several studies published in the early 2000s reported international trends in increased incidence of ICC and decreased inci”